Journal article
The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients
Anne Sofie Hogh Kolbaek Kjaer, Christel Rothe Brinkmann, Charles A Dinarello, Rikke Olesen, Lars Ostergaard, Ole Schmeltz Sogaard, Martin Tolstrup, Thomas Aagaard Rasmussen
AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Abstract
OBJECTIVE: To investigate the effect of the histone deacetylase inhibitor panobinostat on HIV-associated inflammation. DESIGN: Sub-study of a single-arm, phase I/II clinical trial. METHODS: HIV-infected adults on suppressive antiretroviral therapy received oral panobinostat 20 mg three times per week, every other week, for 8 weeks, that is, four cycles of treatment. Plasma levels of high-sensitivity C-reactive protein, matrix metalloproteinase 9, soluble CD40 ligand and interleukin-6 were determined using human ELISA kits. Soluble endothelia selectin (E-selectin) was measured by a multiplex immunoassay. Total monocyte count, phenotype changes on monocytes and monocyte histone acetylation wer..
View full abstractGrants
Awarded by NIH
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding Acknowledgements
The study was funded by the Institute of Clinical Medicine at Aarhus University, by The Danish Council for Strategic Research and by NIH Grant AI-15614 (to C.A.D.). Novartis provided panobinostat for the study.